Abstract
Lung cancer is the main cause of brain metastases. For patients with limited brain metastases, hypofractionated stereotactic radiotherapy (HSRT) has been proven feasible. However, the optimal dose schedule of HSRT remains inconclusive. Our research aims to investigate the dose response and toxicity in patients treated with HSRT.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
